Objectives Glioblastoma multiforme (GBM) is a common and fatal brain tumour in the central nervous system with a poor survival rate and a median survival time of 15 months only. The standard treatment is aggressive surgical resection followed by radiotherapy and chemotherapy. However, effective drugs available in chemotherapy are limited. This study was designed to evaluate, for the first time, the potential therapeutic effect of Cissus quadrangularis (CQ) in human glioblastoma cells and to investigate its possible mechanisms of action. Methods In this study, we examined the anticancer activity of CQ in human glioblastoma U87 MG cells by cell viability assay, cell migration assay, immunofluorescence staining and Western blot. Results ...
Glioblastoma Multiforme (GBM) is classified as a malignant grade IV astrocytoma, and is considered t...
Glioblastoma multiforme (GBM) is the most aggressive and common form of primary brain tumor in adult...
Attempts to treat cancer with drugs that target mutated proteins have met with mixed success. By scr...
Objectives Glioblastoma multiforme (GBM) is a common and fatal brain tumour in the central nervous s...
Cissus quadrangularis (CQ) is a perennial rambling shrub of the grape family commonly known a
Includes bibliographical references.Glioblastoma multiforme (GBM) is the most prevalent and aggressi...
Glioblastoma multiforme (GBM) is the most aggressive, infiltrative brain cancer. Tumour recurrence i...
There is a growing evidence that antimalarial chloroquine could be re-purposed for cancer treatment....
Malignant primary brain tumors remain among the most difficult cancers to treat, in particular, Glio...
Gliomas are the most common tumors in the central nervous system, the average survival time of patie...
Glioblastoma (GBM) is the most common and aggressive malignant grade IV brain tumour. It remains an ...
Chloroquine, one of the oldest antimalarials, has been implicated as a therapeutic sensitizer in dif...
Glioblastoma multiforme (GBM), designated as World Health Organization (WHO) grade IV astrocytoma, i...
Background: Glioblastoma multiforme (GBM), due to its location, aggressiveness, heterogeneity and in...
Targeting epigenetic mechanisms has shown promise against several cancers but has so far been unsucc...
Glioblastoma Multiforme (GBM) is classified as a malignant grade IV astrocytoma, and is considered t...
Glioblastoma multiforme (GBM) is the most aggressive and common form of primary brain tumor in adult...
Attempts to treat cancer with drugs that target mutated proteins have met with mixed success. By scr...
Objectives Glioblastoma multiforme (GBM) is a common and fatal brain tumour in the central nervous s...
Cissus quadrangularis (CQ) is a perennial rambling shrub of the grape family commonly known a
Includes bibliographical references.Glioblastoma multiforme (GBM) is the most prevalent and aggressi...
Glioblastoma multiforme (GBM) is the most aggressive, infiltrative brain cancer. Tumour recurrence i...
There is a growing evidence that antimalarial chloroquine could be re-purposed for cancer treatment....
Malignant primary brain tumors remain among the most difficult cancers to treat, in particular, Glio...
Gliomas are the most common tumors in the central nervous system, the average survival time of patie...
Glioblastoma (GBM) is the most common and aggressive malignant grade IV brain tumour. It remains an ...
Chloroquine, one of the oldest antimalarials, has been implicated as a therapeutic sensitizer in dif...
Glioblastoma multiforme (GBM), designated as World Health Organization (WHO) grade IV astrocytoma, i...
Background: Glioblastoma multiforme (GBM), due to its location, aggressiveness, heterogeneity and in...
Targeting epigenetic mechanisms has shown promise against several cancers but has so far been unsucc...
Glioblastoma Multiforme (GBM) is classified as a malignant grade IV astrocytoma, and is considered t...
Glioblastoma multiforme (GBM) is the most aggressive and common form of primary brain tumor in adult...
Attempts to treat cancer with drugs that target mutated proteins have met with mixed success. By scr...